Does Capmatinib Interact with Mao Inhibitors?
Capmatinib and Mao Inhibitors have a moderate drug interaction according to U.S. FDA drug labeling data. Coadministration with strong CYP3A inhibitors increased capmatinib exposure, which may increase the incidence and severity of adverse reactions. Closely monitor patients for adverse reactions. The mechanism involves cyp3a inhibition increases capmatinib exposure. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Capmatinib and Mao Inhibitors occurs because cyp3a inhibition increases capmatinib exposure. Clinically, this means coadministration with strong cyp3a inhibitors increased capmatinib exposure, which may increase the incidence and severity of adverse reactions. closely monitor patients for adverse reactions. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.
What To Tell Your Doctor or Pharmacist
If you are taking Capmatinib and your doctor is considering prescribing Mao Inhibitors (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider